Form 4: Madrigal Pharmaceuticals Director Paul A. Friedman Reports Changes in Beneficial Ownership

Director Paul A. Friedman reported changes in beneficial ownership of Madrigal Pharmaceuticals stock, including the acquisition of restricted stock units and stock options.

Summary

• On June 25, 2024, Paul A. Friedman, a director of Madrigal Pharmaceuticals, reported changes in his beneficial ownership of the company's stock.
• He acquired 714 shares of common stock through a grant of restricted stock units, which will vest on June 25, 2025, contingent upon continued service with the issuer.
• Friedman also acquired 1,105 stock options with an exercise price of $280.04, vesting fully on June 25, 2025, provided he remains a director until that date.
• Following these transactions, Friedman directly owns 186,449 shares of common stock and indirectly owns 655,540 shares through SQN LLC.
• He disclaims beneficial ownership of the shares held by SQN LLC except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The grant of restricted stock units and stock options to a director aligns his interests with the long-term success of the company.
• The vesting conditions encourage continued service and commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a director, which is a common occurrence.

Stakeholder Impact

• Shareholders are informed about changes in the holdings of a key company director.

Key Dates